KaNDy Therapeutics' Series C Round

KaNDy Therapeutics raised a round of funding on August 29, 2018.

KaNDy Therapeutics is a clinical-stage company focused on optimising the potential of NT-814 in the treatment of female sex-hormone related conditions, with an initial focus on symptoms of the menopau…

Articles about KaNDy Therapeutics' Series C Round: